Keyword Analysis & Research: beigene pharmaceutical

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
beigene pharmaceutical1.250.339651422
beigene1.350.96369117
pharmaceutical1.050.94171314

Keyword Research: People who searched beigene pharmaceutical also searched

Keyword CPC PCC Volume Score
beigene pharmaceutical0.890.8955622
beigene pharmaceutical news0.250.4388374
beigene pharmaceutical location in usa0.410.5516720
beigene pharmaceutical stock1.030.571768
beigene pharmaceutical pipeline1.380.5277295
beigene pharmaceutical nj0.140.666079
beigene pharmaceutical shanghai co. ltd1.480.873256
beigene pharmaceuticals1.251520344

Search Results related to beigene pharmaceutical on Search Engine

  • BeiGene | Cancer Has No Borders. Neither Do We.

    beigene.com

    https://www.beigene.com/

    WEBMar 14, 2024 · BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.

    DA: 92 PA: 60 MOZ Rank: 67

  • BeiGene - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/BeiGene

    WEBBeiGene, Ltd. is a global oncology company [3] that specializes in the development of drugs for cancer treatment. [4] . Founded in 2010 chief executive officer by John V. Oyler and Xiaodong Wang, the multinational company headquartered in Cambridge, Massachusetts has offices in North America, Europe, South America, Asia and Australia.

    DA: 24 PA: 49 MOZ Rank: 66

  • Our Mission, Vision & Values | BeiGene

    beigene.com

    https://www.beigene.com/about/our-company/mission-vision-values/

    WEBValues. Patients First. Stand up for more affordable medicines for patients everywhere and improve global health and well-being . Bold Ingenuity. Challenge the status quo to deliver science once thought to be impossible and make bold commitments and deliver against them . Collaborative Spirit.

    DA: 15 PA: 11 MOZ Rank: 18

  • Our Pipeline | BeiGene

    beigene.com

    https://www.beigene.com/science/pipeline/

    WEBWe are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by cancer type. In addition to leveraging our internal research resources, we continually evaluate external pre-clinical and early-stage assets that might expand our pipeline and contribute to our durable competitive advantages.

    DA: 7 PA: 29 MOZ Rank: 55

  • BeiGene Receives FDA Approval for TEVIMBRA® for the …

    yahoo.com

    https://finance.yahoo.com/news/beigene-receives-fda-approval-tevimbra-202800347.html

    WEBBusiness Wire. March 14, 2024 · 18 min read. Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared...

    DA: 31 PA: 20 MOZ Rank: 82

  • BeiGene Announces Positive Regulatory Updates in Europe and …

    businesswire.com

    https://www.businesswire.com/news/home/20230919543475/en/BeiGene-Announces-Positive-Regulatory-Updates-in-Europe-and-the-U.S.-After-Recently-Regaining-Global-Rights-for-TEVIMBRA%C2%AE/

    WEBSep 19, 2023 · BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®. European Commission approves TEVIMBRA for previously treated advanced or...

    DA: 49 PA: 15 MOZ Rank: 85

  • BeiGene Announces FDA Accelerated Approval of BRUKINSA …

    yahoo.com

    https://finance.yahoo.com/news/beigene-announces-fda-accelerated-approval-221900120.html

    WEBMar 7, 2024 · BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 07, 2024 -- ( BUSINESS WIRE )--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the...

    DA: 41 PA: 9 MOZ Rank: 67

  • BeiGene Announces U.S. FDA Acceptance of Biologics License …

    businesswire.com

    https://www.businesswire.com/news/home/20210912005031/en/BeiGene-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-for-Tislelizumab-in-Esophageal-Squamous-Cell-Carcinoma

    WEBSep 13, 2021 · CAMBRIDGE, Mass. & BEIJING-- ( BUSINESS WIRE )--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines...

    DA: 100 PA: 41 MOZ Rank: 41

  • BeiGene Expands Collaboration with Novartis to Develop and

    businesswire.com

    https://www.businesswire.com/news/home/20211220005226/en/BeiGene-Expands-Collaboration-with-Novartis-to-Develop-and-Commercialize-BeiGene%E2%80%99s-TIGIT-Inhibitor-and-Market-Five-Novartis-Oncology-Medicines-in-China-Broad-Markets

    WEBDec 20, 2021 · Building upon the collaboration between BeiGene and Novartis for anti-PD1 antibody tislelizumab announced in January 2021, BeiGene has granted Novartis an exclusive time-based option under...

    DA: 74 PA: 95 MOZ Rank: 48

  • US FDA approves expanded use of BeiGene's blood cancer drug

    reuters.com

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-expanded-use-beigenes-blood-cancer-drug-2024-03-07/

    WEBMarch 7 (Reuters) - The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK) combination drug to treat certain patients with a type of...

    DA: 79 PA: 1 MOZ Rank: 3